Proteus Syndrome Market Insight, Epidemiology and Market Forecast - 2034The Proteus Syndrome market is entering a pivotal decade, driven by ...

Each year, 1·3 million people die from viral hepatitis, and mortality is increasing.1 This World Hepatitis Day, all stakeholders must break down the barriers to hepatitis elimination, including ending ...

Hepatitis B virus, a killer of more than one million people each year, is a notoriously wily virus, often lingering and ...

A number of stocks jumped in the afternoon session after a new trade agreement between the United States and Japan spurred a ...

Get all latest & breaking news on Corona Remedies. Watch videos, top stories and articles on Corona Remedies at moneycontrol.com.

(Alliance News) - GSK PLC on Wednesday said the US Food & Drug Administration has extended the review period for Blenrep combinations in relapsed/refractory multiple myeloma after an advisory ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment ...

Ozzy Osbourne has been remembered as a “pioneer,” a “fearless talent” and a “dear friend,” in an outpouring of tributes from ...

The rising occurrence of dysmenorrhea, along with greater awareness and advancements in diagnosis, is driving substantial growth in the dysmenorrhea ...

GSK said the U.S. Food and Drug Administration extended its review period for Blenrep combinations to treat patients with relapsed or refractory multiple myeloma.

GSK PLC GSK shares rose 1.78% to £13.72 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.42% to 9,061.49. GSK PLC ...